 Ascendis Pharma AS NASDAQ:ASND was downgraded by research analysts at BidaskClub from a buy rating to a hold rating in a report issued on Saturday, BidAskClub reports. A number of other equities research analysts also recently weighed in on ASND. JPMorgan Chase Co. started coverage on Ascendis Pharma AS in a research report on ... 